Search by drug, manufacturer, or indication

Displaying 811 - 820 of 1165

Onivyde (irinotecan liposome)

Status:

Concluded without agreement

Manufacturer:

Servier Canada Inc.

Indication:

Metastatic Pancreatic Cancer

Last updated June 7, 2019

Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)

Status:

Concluded without agreement

Manufacturer:

Janssen Inc.

Indication:

HIV-1 Infection

Last updated May 22, 2019

Viacoram (perindopril arginine/amlodipine)

Status:

Concluded without agreement

Manufacturer:

Servier Canada Inc.

Indication:

Hypertension

Last updated May 22, 2019

Adcetris (brentuximab vedotin)

Status:

Negotiations were not pursued

Manufacturer:

Seattle Genetics Inc.

Indication:

Hodgkin's Lymphoma

Last updated May 17, 2019

Fasenra (benralizumab)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Eosinophilic Asthma

Last updated May 3, 2019

Probuphine (buprenorphine)

Status:

Concluded with an LOI

Manufacturer:

Knight Therapeutics Inc.

Indication:

Opioid Use Disorder

Last updated May 3, 2019

Kisqali (ribociclib)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Advanced or Metastatic Breast Cancer

Last updated April 26, 2019

Akynzeo (netupitant/palonosetron)

Status:

Concluded with an LOI

Manufacturer:

Purdue Pharma

Indication:

Nausea and vomiting (chemotherapy induced) prevention

Last updated April 24, 2019

Duodopa (levodopa/carbidopa)

Status:

Concluded with an LOI

Manufacturer:

AbbVie Corporation

Indication:

Parkinson's disease

Last updated April 18, 2019

Eucrisa (crisaborole)

Status:

Negotiations were not pursued

Manufacturer:

Pfizer Canada ULC

Indication:

Atopic dermatitis

Last updated April 16, 2019